ImmunityBio (IBRX) Asset Writedowns and Impairment (2014 - 2023)

ImmunityBio (IBRX) has reported Asset Writedowns and Impairment for 4 consecutive years, with $886000.0 the latest figure, recorded in Q4 2023.

• In Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to $886000.0; the TTM figure through Dec 2023 stood at -$9.8 million (changed N/A YoY), while the FY2023 annual figure was $886000.0, up 30.1% from the prior year.
• Asset Writedowns and Impairment climbed to $886000.0 in Q4 2023 per IBRX's latest filing, from -$10.7 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $10.7 million in Q3 2020 and bottomed at -$10.7 million in Q4 2020.
• Historically, Asset Writedowns and Impairment has averaged $402500.0 across 3 years, with a median of $805000.0 in 2019.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 1572.38% in 2020 and fell as far as 1572.38% in 2020.
• ImmunityBio's Asset Writedowns and Impairment stood at $724000.0 in 2019, then slumped by 1572.38% to -$10.7 million in 2020, then jumped by 108.31% to $886000.0 in 2023.
• Business Quant data shows IBRX's Asset Writedowns and Impairment at $886000.0 in Q4 2023, -$10.7 million in Q4 2020, and $10.7 million in Q3 2020.